Sanofi Targets 18 Drug Launches From 2012 To 2015
This article was originally published in Pharmaceutical Approvals Monthly
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.
You may also be interested in...
Lupin Pharmaceuticals had filed a citizen petition arguing that Teva was not entitled to the first-mover 180-day exclusivity because it failed to get tentative approval within 30 months, but FDA said that it had changed its criteria and requested additional testing.
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
Sanofi is through the worst of its patent cliff and can deliver sales growth of at least 5% per year, on average, between 2012 and 2015, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts. And if 5% is a far cry from the double-digit pharma growth of yesteryear, investors may take heart from higher earnings growth, thanks in large part to an additional €2 billion ($2.8 billion) worth of cost savings and pared down R&D spend – and the promise of a higher dividend.